Dopamine agonist increases risk taking but blunts reward-related brain activity

129Citations
Citations of this article
166Readers
Mendeley users who have this article in their library.

Abstract

The use of D2/D3 dopaminergic agonists in Parkinson's disease (PD) may lead to pathological gambling. In a placebo-controlled double-blind study in healthy volunteers, we observed riskier choices in a lottery task after administration of the D3 receptor-preferring agonist pramipexole thus mimicking risk-taking behavior in PD. Moreover, we demonstrate decreased activation in the rostral basal ganglia and midbrain, key structures of the reward system, following unexpected high gains and therefore propose that pathological gambling in PD results from the need to seek higher rewards to overcome the blunted response in this system. © 2008 Riba et al.

Cite

CITATION STYLE

APA

Riba, J., Krämer, U. M., Heldmann, M., Richter, S., & Münte, T. F. (2008). Dopamine agonist increases risk taking but blunts reward-related brain activity. PLoS ONE, 3(6). https://doi.org/10.1371/journal.pone.0002479

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free